Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antithyroid drug regimen for treating Graves' hyperthyroidism.

P Abraham1, A Avenell, W A Watson

  • 1Endocrinology, University of Aberdeen, Ward 27/28, Aberdeen Royal Infirmary, Aberdeen, Scotland, UK, AB25 2ZN. p.abraham@arh.grampian.scot.nhs.uk

The Cochrane Database of Systematic Reviews
|April 23, 2005
PubMed
Summary

Optimal duration for antithyroid drug therapy in Graves' hyperthyroidism is 12-18 months using the titration regimen. The titration regimen also showed fewer adverse effects compared to the block-replace regimen, with no added benefit from thyroxine supplementation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Cost-effectiveness of bariatric surgery and non-surgical weight management programmes for adults with severe obesity: a decision analysis model.

International journal of obesity (2005)·2021
Same author

Cost-effectiveness of bariatric surgery and non-surgical weight management programmes for adults with severe obesity: a decision analysis model.

International journal of obesity (2005)·2021
Same author

Empirically generated reference proportions for baseline p values from rounded summary statistics.

Anaesthesia·2020
Same author

Corrigendum to Rounding, but not randomization method, non-normality, or correlation, affected baseline P-value distributions in randomized trials. J Clin Epidemiol 2019;110:50-62.

Journal of clinical epidemiology·2020
Same author

A systematic review of UK-based long-term nonsurgical interventions for people with severe obesity (BMI ≥35 kg m<sup>-2</sup> ).

Journal of human nutrition and dietetics : the official journal of the British Dietetic Association·2020
Same author

Inaccurate retraction notice for meta-analysis by Iwamoto et al.

Acta neurologica Scandinavica·2018

Area of Science:

  • Endocrinology
  • Pharmacology
  • Clinical Medicine

Background:

  • Antithyroid drugs are standard treatment for hyperthyroidism.
  • Significant variability exists in prescribed dosages, regimens, and treatment durations.

Purpose of the Study:

  • To evaluate the impact of antithyroid drug dosage, regimen, and duration on Graves' hyperthyroidism outcomes.
  • To compare different treatment strategies for managing hyperthyroidism.

Main Methods:

  • Systematic review and meta-analysis of randomized and quasi-randomized controlled trials.
  • Searched multiple databases including Cochrane Central Register, MEDLINE, EMBASE, BIOSIS, CINAHL, HEALTHSTAR.
  • Included 23 trials with 3115 participants; assessed trial quality and extracted data.

Related Experiment Videos

Main Results:

  • Longer duration therapy (18 months) using the titration regimen reduced relapse rates compared to 6-month therapy.
  • The block-replace regimen showed no significant difference in relapse rates between 6 and 12 months.
  • Titration regimen had fewer adverse effects (rashes, withdrawals) than the block-replace regimen.
  • Adding thyroxine post-treatment did not significantly reduce hyperthyroidism recurrence.

Conclusions:

  • Optimal duration for the titration regimen appears to be 12-18 months for managing Graves' hyperthyroidism.
  • The block-replace regimen (6 months) was as effective as 12-month treatment in one study.
  • The titration regimen is associated with fewer side effects and comparable efficacy to the block-replace regimen.
  • Thyroxine supplementation after initial antithyroid therapy offers no discernible benefit for preventing hyperthyroidism relapse.